• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

    16.46 +0.45 (+2.81%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 959,363
    Open 15.88
    Bid (Size) 15.43 (400)
    Ask (Size) 16.55 (600)
    Prev. Close 16.01
    Today's Range 15.78 - 16.46
    52wk Range 4.200 - 18.61
    Shares Outstanding 67,176,067
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +44.1%
    +44.1%
    1 Month
    +10.1%
    +10.1%
    3 Month
    +12.2%
    +12.2%
    6 Month
    +21.0%
    +21.0%
    1 Year
    +209.4%
    +209.4%

    More News

    Read More
    News headline image
    Amylyx (AMLX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data ↗
    Via Chartmill
    News headline image
    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
    Via The Motley Fool
    News headline image
    Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
    Via The Motley Fool
    News headline image
    Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
    From Rosen Law Firm
    Via Business Wire
    News headline image
    Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028 ↗
    Via Chartmill

    Frequently Asked Questions

    Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
    Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
    What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
    The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 16.46
    When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 05/04/26 04:00 PM ET
    What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 1.11B
    How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?
    Amylyx Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.